110 related articles for article (PubMed ID: 36089245)
21. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
[TBL] [Abstract][Full Text] [Related]
22. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
23. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K
Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887
[TBL] [Abstract][Full Text] [Related]
24. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
[TBL] [Abstract][Full Text] [Related]
25. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
26. Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
Winter JM; Curry NL; Gildea DM; Williams KA; Lee M; Hu Y; Crawford NPS
BMC Genomics; 2018 Jun; 19(1):450. PubMed ID: 29890952
[TBL] [Abstract][Full Text] [Related]
27. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
28. Alternative splicing regulation by the androgen receptor in prostate cancer cells.
Germain L; Lafront C; Beaudette J; Karthik Poluri RT; Weidmann C; Audet-Walsh É
J Steroid Biochem Mol Biol; 2020 Sep; 202():105710. PubMed ID: 32534106
[TBL] [Abstract][Full Text] [Related]
29. HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness.
Ho JS; Di Tullio F; Schwarz M; Low D; Incarnato D; Gay F; Tabaglio T; Zhang J; Wollmann H; Chen L; An O; Chan THM; Hall Hickman A; Zheng S; Roudko V; Chen S; Karz A; Ahmed M; He HH; Greenbaum BD; Oliviero S; Serresi M; Gargiulo G; Mann KM; Hernando E; Mulholland D; Marazzi I; Wee DKB; Guccione E
Elife; 2021 Jun; 10():. PubMed ID: 34075878
[TBL] [Abstract][Full Text] [Related]
30. Periostin: a promising target of therapeutical intervention for prostate cancer.
Sun C; Zhao X; Xu K; Gong J; Liu W; Ding W; Gou Y; Xia G; Ding Q
J Transl Med; 2011 Jun; 9():99. PubMed ID: 21714934
[TBL] [Abstract][Full Text] [Related]
31. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
32. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
33. SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.
Yuan D; Wang W; Su J; Zhang Y; Luan B; Rao H; Cheng T; Zhang W; Xiao S; Zhang M; Jiang FN; Sun Z; Jia Z; Zhong WD; Zhu J
Curr Cancer Drug Targets; 2018; 18(9):894-904. PubMed ID: 29295692
[TBL] [Abstract][Full Text] [Related]
34. PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
Li E; Liu L; Li F; Luo L; Zhao S; Wang J; Kang R; Luo J; Zhao Z
Prostate; 2017 Dec; 77(16):1563-1572. PubMed ID: 28971496
[TBL] [Abstract][Full Text] [Related]
35. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
37. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
Daouk R; Bahmad HF; Saleh E; Monzer A; Ballout F; Kadara H; Abou-Kheir W
PLoS One; 2020; 15(8):e0237442. PubMed ID: 32790767
[TBL] [Abstract][Full Text] [Related]
39. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
40. Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer.
Naro C; Antonioni A; Medici V; Caggiano C; Jolly A; de la Grange P; Bielli P; Paronetto MP; Sette C
J Exp Clin Cancer Res; 2024 Feb; 43(1):58. PubMed ID: 38413979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
